Literature DB >> 3830242

Pharmacokinetic interactions between felodipine and metoprolol.

S R Smith, M R Wilkins, D B Jack, M J Kendall, S Laugher.   

Abstract

This double-blind, cross-over study in healthy male subjects evaluated the pharmacokinetics of felodipine and metoprolol given both separately and in combination. During three, five-day study periods, felodipine 10 mg b.d., metoprolol 100 mg b.d. and a combination of the two, were given in random order. There was at least a 7-day washout period between each pharmacokinetic study day. Plasma levels of unchanged felodipine and metoprolol were measured for 24 h after the last dose, on the 5th day of each treatment period. Eight subjects, aged 19-22 years, completed the study. Both felodipine and metoprolol, given alone and in combination, were well tolerated. None of the felodipine pharmacokinetic variables (tmax, Cmax, Cmin, AUC (0-12) and t1/2) changed significantly when felodipine and metoprolol were given in combination. Cmax and AUC (0-12) for metoprolol increased significantly when metoprolol and felodipine were combined, although tmax, Cmin and t1/2 for metoprolol remained unchanged. The changes in metoprolol pharmacokinetics induced by felodipine are small and unlikely to be clinically important.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3830242     DOI: 10.1007/bf00606633

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  9 in total

1.  Quantitative determination of metoprolol in plasma and urine by gas chromatography.

Authors:  M Ervik
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1975

2.  Separate and combined effects of nadolol and nifedipine on the cardiac response to exercise.

Authors:  M R Wilkins; K L Woods; D B Jack; M J Kendall; S J Laugher
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

3.  Determination of felodipine in plasma by capillary gas chromatography with electron capture detection.

Authors:  M Ahnoff
Journal:  J Pharm Biomed Anal       Date:  1984       Impact factor: 3.935

4.  The effect of hydralazine on the pharmacokinetics of three different beta adrenoceptor antagonists: metoprolol, nadolol, and acebutolol.

Authors:  D B Jack; M J Kendall; S Dean; S J Laugher; R Zaman; M E Tenneson
Journal:  Biopharm Drug Dispos       Date:  1982 Jan-Mar       Impact factor: 1.627

5.  Interaction between oral propranolol and hydralazine.

Authors:  A J McLean; H Skews; A Bobik; F J Dudley
Journal:  Clin Pharmacol Ther       Date:  1980-06       Impact factor: 6.875

6.  Lack of a pharmacokinetic interaction between nifedipine and the beta-adrenoceptor blockers metoprolol and atenolol.

Authors:  M J Kendall; D B Jack; S J Laugher; J Lobo; S Rolf Smith
Journal:  Br J Clin Pharmacol       Date:  1984-09       Impact factor: 4.335

7.  Absorption, distribution and elimination of felodipine in man.

Authors:  B Edgar; K J Hoffmann; P Lundborg; C G Regårdh; O Rönn; L Weidolf
Journal:  Drugs       Date:  1985       Impact factor: 9.546

8.  Antihypertensive effect of felodipine combined with beta-blockade. A comparison between 2 and 3 daily dosages.

Authors:  B G Hansson; G Lyngstam; O Lyngstam; L Rydén; U Thilén
Journal:  Drugs       Date:  1985       Impact factor: 9.546

9.  Comparative trial of felodipine and nifedipine in refractory hypertension.

Authors:  H Aberg; M Lindsjö; B Mörlin
Journal:  Drugs       Date:  1985       Impact factor: 9.546

  9 in total
  12 in total

1.  A study of the acute pharmacodynamic interaction of ramipril and felodipine in normotensive subjects.

Authors:  A D Bainbridge; R J MacFadyen; K R Lees; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

Review 2.  Pharmacokinetic interactions with calcium channel antagonists (Part II).

Authors:  K D Schlanz; S A Myre; M B Bottorff
Journal:  Clin Pharmacokinet       Date:  1991-12       Impact factor: 6.447

3.  The interactions between nisoldipine and two beta-adrenoceptor antagonists--atenolol and propranolol.

Authors:  H L Elliott; P A Meredith; C McNally; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

4.  Evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions.

Authors:  Ben D Snyder; Andrew Rowland; Thomas M Polasek; John O Miners; Matthew P Doogue
Journal:  Eur J Clin Pharmacol       Date:  2014-07-17       Impact factor: 2.953

Review 5.  Clinical pharmacokinetics of calcium antagonists. An update.

Authors:  J G Kelly; K O'Malley
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

Review 6.  Felodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Authors:  E Saltiel; A G Ellrodt; J P Monk; M S Langley
Journal:  Drugs       Date:  1988-10       Impact factor: 9.546

Review 7.  Calcium antagonists. Drug interactions of clinical significance.

Authors:  T Rosenthal; D Ezra
Journal:  Drug Saf       Date:  1995-09       Impact factor: 5.606

Review 8.  Clinical pharmacokinetics of felodipine. A summary.

Authors:  B Edgar; P Lundborg; C G Regårdh
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 9.  Felodipine/metoprolol: a review of the fixed dose controlled release formulation in the management of essential hypertension.

Authors:  M Haria; G L Plosker; A Markham
Journal:  Drugs       Date:  2000-01       Impact factor: 9.546

Review 10.  Felodipine clinical pharmacokinetics.

Authors:  P H Dunselman; B Edgar
Journal:  Clin Pharmacokinet       Date:  1991-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.